Bayer's Dual-Pronged Strategy: Legal Resolution and Pricing Shifts

Bayer faces a key Supreme Court hearing on glyphosate lawsuits while pursuing drug price hikes in Europe and Japan to offset U.S. reforms, shaping its financial future.

Investors in Bayer are closely monitoring two critical and simultaneous developments that could fundamentally reshape the company's financial trajectory. The German conglomerate is navigating a potential landmark resolution to its costly glyphosate litigation in the United States while simultaneously embarking on an aggressive new pricing strategy for its pharmaceutical products in key international markets. This dual approach presents significant opportunities for improving the mid-term financial outlook of the Leverkusen-based group.

Pharmaceutical Division Pursues Price Increases

Away from the courtroom, a strategic shift is underway in Bayer's pharmaceutical business. Stefan Oelrich, the division's board member, is actively preparing governments across Europe and Japan for higher drug prices. This initiative is a direct response to regulatory changes in the United States, where a government order now compels pharmaceutical firms to align their U.S. pricing with international levels. To offset the enforced discounts for American consumers, Bayer is seeking price premiums in other affluent nations and has issued warnings about potential delays in launching new medicines in Europe. The division's operational performance strengthens its negotiating position, having secured five major new drug approvals in 2025.

Legal Battleground Nears a Climax

On the legal front, Bayer is approaching a pivotal moment in its long-running glyphosate saga. The U.S. Supreme Court is set to hear a case that could definitively end the multibillion-dollar litigation legacy. The justices will determine whether state-level lawsuits alleging a lack of cancer warnings on Roundup labels are permissible, given that the U.S. Environmental Protection Agency (EPA) classifies the herbicide as safe. Notably, the company has received support from the Trump administration, which has sided with Bayer in this proceeding.

Recent legislative developments have provided the company with favorable momentum ahead of the hearing. In Kentucky, the state legislature recently overrode the governor's veto to pass a law shielding Bayer from lawsuits at the state level. The financial scale of these legal disputes remains colossal. Since acquiring Monsanto in 2018, the company has already disbursed more than $11 billion in settlements and judgments. Management continues to anticipate a negative free cash flow for 2026 due to ongoing litigation-related payments. Despite this, investor optimism for a near-term legal resolution is evident in the share price, which has surged approximately 86% over the past 12 months, recently trading at €39.44.

A Pivotal Week for Shareholders

Key events for Bayer and its shareholders are concentrated in a tight timeframe at the end of April 2026:

• April 24, 2026: Virtual Annual Shareholders' Meeting
• April 27, 2026: U.S. Supreme Court hearing
• April 27, 2026: Ex-dividend date (proposed dividend: €0.11 per share)
• April 29, 2026: Scheduled dividend payment

The Supreme Court's forthcoming decision is critical. A ruling that prohibits state-level lawsuits would remove one of the largest historical burdens on the company's finances, potentially allowing management to initiate its planned financial turnaround starting in 2027 as projected.